Re: Dimar JR, Glassman SD, Burkus KJ, et al. Clinical outcomes and fusion success at 2 years of single-level instrumented posterolateral fusions with recombinant human bone morphogenetic protein-2/compression resistant matrix versus iliac crest bone graft. Spine 2006; 31:2534-40.
Gill
J Brian
JB
D055396:Bone Morphogenetic Protein 2; D019485:Bone Morphogenetic Proteins / Q000008:administration & dosage* / Q000191:economics; D016025:Bone Transplantation / Q000379:methods*; D003362:Cost-Benefit Analysis; D003627:Data Interpretation, Statistical; D006801:Humans; D007085:Ilium / Q000637:transplantation*; D008159:Lumbar Vertebrae / Q000187:drug effects* / Q000601:surgery*; D011994:Recombinant Proteins / Q000008:administration & dosage* / Q000191:economics; D012107:Research Design; D013123:Spinal Fusion / Q000191:economics / Q000379:methods*; D016212:Transforming Growth Factor beta / Q000008:administration & dosage* / Q000191:economics; D016896:Treatment Outcome
D055396:Bone Morphogenetic Protein 2; D019485:Bone Morphogenetic Proteins; D011994:Recombinant Proteins; D016212:Transforming Growth Factor beta; C499469:recombinant human bone morphogenetic protein-2